**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 44926

**Manuscript Type:** CASE REPORT

**Villous adenoma coexistent with focal well-differentiated adenocarcinoma of female urethral orifice: A case report and review of literature**

Qin LF *et al.* Villous adenoma coexistent with adenocarcinoma of female urethra

**Lu-Feng Qin, Ye Liang, Xiao-Ming Xing, Hui Wu, Xue-Cheng Yang, Hai-Tao Niu**

**Lu-Feng Qin, Ye Liang,** **Hui Wu, Xue-Cheng Yang, Hai-Tao Niu,** Department of Urology, Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong Province, China

**Lu-Feng Qin, Ye Liang,** **Hui Wu, Xue-Cheng Yang, Hai-Tao Niu,** Key Laboratory of Urinary System Diseases, Qingdao 266003, Shandong Province, China

**Lu-Feng Qin,** **Hui Wu,** Department of Medicine, Qingdao University, Qingdao 266003, Shandong Province, China

**Xiao-Ming Xing,** Department of Pathology, Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong Province, China

**ORCID number:** Lu-Feng Qin (0000-0001-8727-8627); Ye Liang (0000-0002-3035-0381); Xiao-Ming Xing (0000-0002-1444-7773); Hui Wu (0000-0001-7709-4816); Xue-Cheng Yang (0000-0002-6860-7330); Hai-Tao Niu (0000-0002-9094-2151).

**Author contributions:** Qin LF, Liang Y, Yang XC, Xing XM, and Niu HT collected the case data; Qin LF wrote the manuscript; Niu HT revised the manuscript.

**Informed consent statement:** All patients completed informed consent forms.

**Conflict-of-interest statement:** None of the authors have a conﬂict of interest to report.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Corresponding author:** **Hai-Tao Niu, MD, Doctor, Professor, Surgeon, Surgical Oncologist,** Department of Urology, Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao 266003, Shandong Province, China. niuhttg@163.com

**Telephone:** +86-532-82911953

**Received:** December 3, 2018

**Peer-review started:** December 6, 2018

**First decision:** December 15, 2018

**Revised:** January 2, 2019

**Accepted:** January 26, 2019

**Article in press:**

**Published online:**

**Abstract**

***BACKGROUND***

Villous adenomas of the urinary tract are uncommon. They are morphologically similar to and difficult to differentiate from their counterpart in the colon. The histogenesis and malignant potential are uncertain.

***CASE SUMMARY***

A 63-year-old woman was admitted to our hospital with a mass in the urethral orifice. Gross and microscopic pathological examination was suggestive of urethral villous adenoma with focal well-differentiated adenocarcinoma. The whole urethra and part of the bladder were excised. No further treatment was offered. Carcinoembryonic antigen, cytokeratin 7, cytokeratin 20, epithelial membrane antigen, and p53 protein were positive, and the ratio of Ki-67 was 60%. After follow-up at 11 mo, the patient was cured and had no recurrence.

***CONCLUSION***

Immunohistochemistry is important for differential diagnosis of villous adenoma of the urinary system. Complete surgical resection of the urinary tract is curative.

**Key words:** Villous adenoma; Well-differentiated adenocarcinoma; Urinary tract; Immunohistochemistry; Case report

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Villous adenoma coexisting with adenocarcinoma of the urinary system is uncommon. Differential diagnosis from villous adenoma of the digestive tract is difficult. We present a case of villous adenoma coexisting with adenocarcinoma of the female urethral orifice and provide an accurate method to differentiate villous adenomas of the urinary and digestive tracts.

Qin LF, Liang Y, Xing XM, Wu H, Yang XC, Niu HT. Villous adenoma coexistent with focal well-differentiated adenocarcinoma of female urethral orifice: A case report and review of literature. *World J Clin Cases* 2019; In press

**INTRODUCTION**

Villous adenomas are frequent benign tumors of the digestive tract. However, they are uncommon in the urinary system. To date, only two case series[1,2] and several sporadic cases have been reported in the English language literature. In the urinary tract, villous adenoma has a predilection for the bladder and urachus, followed by the urethra and prostate[1-5]. As far as we know, this is the first case of villous adenoma coexistent with focal well-differentiated adenocarcinoma of the female urethral orifice. We also include a review of the relevant literature.

**CASE PRESENTATION**

***Clinical observations***

A 63-year-old woman was admitted to our hospital in December 2017 with a mass in the urethral orifice. She had noticed the mass 2 years prior without any diagnosis and treatment, and it had slowly increased in size in the past few months. She had no other symptoms. Physical examination found a fleshy, hemorrhaged, uneven polypoidal mass 3 cm × 4 cm in diameter located at the bottom right of the urethral orifice. Radiographic examination of the chest, abdomen, and pelvis was unremarkable. Urine analysis showed that urinary occult blood test was positive and 65.34 red blood cells were observed per high-power field. There was no significant past medical history except for hypertension, and other laboratory tests were normal. Cystourethroscopy demonstrated a villous mass with exophytic growth in the distal urethra and smooth mucosa of the bladder. Biopsy of the urethral lesion showed villous adenoma with well-differentiated adenocarcinoma. Complete gastrointestinal evaluation failed to find any similar lesions. The whole urethra and part of the bladder were excised and the specimen was sent to the Department of Pathology for pathological and immunohistochemical examination. No further treatment was offered. After follow-up at 11 mo, the patient had no recurrence. Publication of this case report was approved by the Ethics Committee of Affiliated Hospital of Qingdao University.

***Pathological evaluation***

The excised lesion was a soft grayish mass measuring 1.5 cm in diameter and appeared papillary and fleshy with hemorrhage and negative surgical margins. The appearance was identical to villous adenoma of the colon. Several blunt finger-like processes lined by pseudostratified columnar cells with frequent goblet cells were observed under a light microscope (Figure 1A). The nuclei were stratified atypical and hyperchromatic. Abundant mucin was seen both intracellularly and extracellularly (Figure 1B). Carcinomatous areas consisted of dysplastic glands and some of the glands presented with high-grade intraepithelial neoplasia (Figure 1C). In focal areas, the glandular component was characterized by increased disorganization of structure. More importantly, the carcinoma invaded the muscularis layer. The gross and microscopic examination was suggestive of urethral villous adenoma with focal well-differentiated adenocarcinoma.

***Immunohistochemical analysis***

Formalin-fixed, paraffin-embedded tissue was cut into 5-µm sections for immunohistochemical evaluation. Immunohistochemical examination was positive for carcinoembryonic antigen (CEA), cytokeratin (CK) 7, CK20, epithelial membrane antigen (EMA), and p53 protein, and the positive ratio of Ki-67 was 60% in the adenocarcinoma (Figure 2). All immunohistochemical staining was carried out by the avidin–biotin–complex method, as previously described[6,7].

***Literature review***

We carried out a review of the literature on urethral villous adenoma. PubMed and Embase were searched using the following keywords: urethra OR urethral AND villous adenoma. We only included articles in English. A total of 11 cases with urethral villous adenoma were reported from 1981 to 2003 (Table 1).

**FINAL DIAGNOSIS**

The final diagnosis of the patient was urethral villous adenoma with focal well-differentiated adenocarcinoma.

**TREATMENT**

The whole urethra and part of the bladder of the patients were excised under general anesthesia.

**OUTCOME AND FOLLOW-UP**

After follow-up at 11 mo, the patient had no recurrence.

**DISCUSSION**

Villous adenoma of the urinary tract is uncommon and occurs principally in elderly patients, without gender predominance, and is mostly located in the urachus and bladder, followed by the urethra and ureter[1-5]. The typical clinical presentation includes hematuria and urinary tract irritation[1-5].

The gross and microscopic characteristics of urinary villous adenoma are identical to those of gastrointestinal villous adenoma. Pure villous adenomas are usually small and solitary. The tumors show papillary or finger-like processes and have a soft texture without prominent hemorrhage and necrosis. Microscopically, they all exhibit papillary architecture with central lamina propria cores, consisting of pointed or blunt finger-like processes lined by pseudostratified columnar epithelial cells with goblet-type cells. Nuclear atypia is common[1,14-16]. Adenocarcinoma presents with brittle texture, erosion, and hemorrhage. Microscopically, the pseudostratified columnar epithelial cells show stratification, crowding, hyperchromasia, and irregular nuclear mitosis[1].The pathological diagnosis of our case was villous adenoma coexistent with focal well-differentiated adenocarcinoma. The gross and microscopic presentations were consistent with previous reports.

As for the immunophenotypic profile, we found that CEA, CK7, CK20, EMA, and p53 were positive and the positive ratio of Ki-67 was 60%. As reported previously[1,2,17], almost all the tumor lesions were stained for CEA and CK20 and approximately 50% for CK7, but generally EMA was negative. Cheng *et al*[1] reported that CK7 was positive in 56% of patients with urinary tract adenoma and 22% were positive for EMA. The immunohistochemical staining patterns were also identical with those of intestinal villous adenoma. Our results were consistent with prior studies.

The etiopathogenesis of urinary tract villous adenoma is not entirely understood. Atik *et al*[18] hypothesized that embryologically the urinary tract and distal colorectum both arise from partitioning of the cloaca. The cloaca is divided into two parts by the urorectal septum. The dorsal side of the cloaca turns into the rectum and the ventral side of cloaca into the urogenital sinus. The former splits into three sections: presumptive bladder, pelvic urethra, and presumptive definitive urogenital sinus, which becomes the vaginal vestibule, and the glandular remnant in the bladder or urethra may give rise to these villous tumors. Based on this pathogenic hypothesis, villous adenomas in the bladder, urethra, and vaginal vestibule have been reported[9]. There is another assumption that these lesions originate from injured urothelial stem cells due to long-term irritation, such as chronic infection and chemical injury, which result in glandular metaplasia[1,2,19,20]. In our case, we found that CK7, CK20 and EMA were positive, which was similar to the immunophenotype in primary villous adenoma of the intestinal tract. Based on this result, we assume that the pluripotent stem cells with glandular differentiation capability might cause intestinal metaplasia and be the origin of adenocarcinoma.

The current studies have suggested that villous adenoma is a well-recognized premalignant lesion of the colon. Villous adenoma of the urinary tract shares the same origins as colon villous adenoma and can be considered as a potential precursor of adenocarcinoma of the urinary tract[21]. Villous adenoma of the urinary tract coexistent with *in situ* or invasive adenocarcinoma shows marked dysplastic pseudostratified epithelium with enlarged, crowded, and hyperchromatic nuclei[1,21-23]. Adegboyega *et al*[4] found that villous adenoma of the bladder was heteroploid with high expression of p53, which suggests the potential carcinogenesis of the benign tumor. In addition, both villous adenoma and adenocarcinoma of the bladder are commonly located in the dome of the bladder and urachus. They have similar immunohistochemical features and diffuse expression of CEA, demonstrating that adenocarcinoma originates from villous adenoma[1]. Our case presented with villous adenoma with focal well-differentiated adenocarcinoma, suggesting that villous adenoma in the urinary tract has similar malignant transformation from adenoma to adenocarcinoma to that in the gastrointestinal tract. Therefore, villous adenoma of the urinary tract should be removed completely and sampled adequately to avoid leaving out any malignant lesions.

As the villous adenoma can transform from benign tumor to malignant adenocarcinoma, the latter two share identical morphological and immunohistochemical features. It is important to make a differential diagnosis between villous adenoma of the urinary tract and secondary involvement from adjacent anatomical sites and particularly metastases, such as from the colon, female genital tract, and prostate gland[1,2,4]. For most patients with prostatic adenocarcinoma, morphological features can be easily identified by histology alone with positive prostatic adenocarcinomas[24]. For female patients with adenocarcinoma of the genital system, carbohydrate antigen 125, estrogen receptor, and progesterone receptor can be specific diagnostic tumor markers. Unfortunately, histological examination is impossible to differentiate urinary tract villous adenoma from metastatic adenocarcinoma of the gastrointestinal tract and there is no specific tumor marker. Wang *et al*[25] have found that a panel consisting of CK7 and CK20 has some value in differentiating primary bladder adenocarcinoma from metastatic colorectal adenocarcinoma. Nuclear staining for CK20 favors colorectal origin, while primary bladder adenocarcinoma is usually positive for CK7[25,26]. However, clinical history and colonoscopic findings are essential to reach the correct diagnosis in most cases. Differentiation of villous adenoma with coexistent adenocarcinoma in the urinary tract from secondary involvement by colonic cancer may be impossible on morphological grounds alone, although clinical presentation, endoscopic examination, radiographic studies, and histological findings suggest a primary bladder neoplasm[27]. In our case, there were no positive radiographic examinations and complete gastrointestinal evaluation. Immunohistochemical examination was helpful in drawing the conclusion that the urethral tumor in our case was a primary neoplasm.

Patients with pure villous adenoma in the urinary tract have excellent prognosis. It has been demonstrated that surgical excision of the lesion is the most effective approach, allowing for a long-term disease-free period postoperatively. There has been no recurrence or invasive adenocarcinoma in any patients with isolated villous adenoma during a mean follow-up of 9.9 years[1]. Even patients with *in situ* adenocarcinoma have shown satisfactory outcome after complete surgical resection[1,28]. However, it is uncertain whether an untreated lesion might eventually develop into an adenocarcinoma[2]. In our case, the mass was found 2 years ago without any diagnosis and treatment. The pathological results of the surgical specimen showed that the glandular structure was disordered with loss of polarity and nuclear atypia. The suggested diagnosis was villous adenoma with focal well-differentiated adenocarcinoma. Therefore, strict follow-up and periodical re-examination are essential because of malignant transformation of the tumor. In our case, there has been no recurrence over the past 11 mo.

***Conclusions***

In summary, villous adenoma of the urinary tract usually occurs in elderly patients, with a predilection for the urachus, dome, and trigone of the urinary bladder, but rarely for the urethra. Immunohistochemistry is important for the differential diagnosis of villous adenoma of the urinary tract. Patients with isolated villous adenoma have excellent prognosis, and surgical excision might be a good treatment choice and offer long-term survival. Patients with coexistent adenocarcinoma may experience recurrence or distant metastasis, and more aggressive treatments may be indicated. Further study is needed to establish the precursor nature of this uncommon lesion.

**REFERENCES**

1 **Cheng L**, Montironi R, Bostwick DG. Villous adenoma of the urinary tract: a report of 23 cases, including 8 with coexistent adenocarcinoma. *Am J Surg Pathol* 1999; **23**: 764-771 [PMID: 10403298 DOI: 10.1097/00000478-199907000-00003]

2 **Seibel JL**, Prasad S, Weiss RE, Bancila E, Epstein JI. Villous adenoma of the urinary tract: a lesion frequently associated with malignancy. *Hum Pathol* 2002; **33**: 236-241 [PMID: 11957151 DOI: 10.1053/hupa.2002.31293]

3 **Sung W**, Park BD, Lee S, Chang SG. Villous adenoma of the urinary bladder. *Int J Urol* 2008; **15**: 551-553 [PMID: 18489648 DOI: 10.1111/j.1442-2042.2008.02041.x]

4 **Adegboyega PA**, Adesokan A. Tubulovillous adenoma of the urinary bladder. *Mod Pathol* 1999; **12**: 735-738 [PMID: 10430279 DOI: 10.1121/1.427023]

5 **Eble JN**, Hull MT, Rowland RG, Hostetter M. Villous adenoma of the urachus with mucusuria: a light and electron microscopic study. *J Urol* 1986; **135**: 1240-1244 [PMID: 3712579 DOI: 10.1016/S0022-5347(17)46056-3]

6 **Hsu SM**, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. *J Histochem Cytochem* 1981; **29**: 577-580 [PMID: 6166661 DOI: 10.1177/29.4.6166661]

7 **Lopez-Beltran A**, Pacelli A, Rothenberg HJ, Wollan PC, Zincke H, Blute ML, Bostwick DG. Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases. *J Urol* 1998; **159**: 1497-1503 [PMID: 9554341 DOI: 10.1097/00005392-199805000-00023]

8 **Powell I**, Cartwright H, Jano F. Villous adenoma and adenocarcinoma of female urethra. *Urology* 1981; **18**: 612-614 [PMID: 7314365 DOI: 10.1016/0090-4295(81)90471-4]

9 **Howells MR**, Baylis MS. Benign urethral villous adenoma. Case report. *Br J Obstet Gynaecol* 1985; **92**: 1070-1071 [PMID: 4052350 DOI: 10.1111/j.1471-0528.1985.tb03007.x]

10 **Raju GC**, Roopnarinesingh A, Woo J. Villous adenoma of female urethra. *Urology* 1987; **29**: 446-447 [PMID: 3564224 DOI: 10.1016/0090-4295(87)90523-1]

11 **Morgan DR**, Dixon MF, Harnden P. Villous adenoma of urethra associated with tubulovillous adenoma and adenocarcinoma of rectum. *Histopathology* 1998; **32**: 87-89 [PMID: 9522225 DOI: 10.1046/j.1365-2559.1998.0241e.x]

12 **Sung MT**, Lin JW, Chen WJ. Villous adenomas of the urinary tract: report of two cases. *Chang Gung Med J* 2000; **23**: 291-295 [PMID: 10916230 DOI: 10.1113/jphysiol.1959.sp006228]

13 **Noel JC**, Fayt I, Aguilar SF. Adenosquamous carcinoma arising in villous adenoma from female vulvar urethra. *Acta Obstet Gynecol Scand* 2006; **85**: 373-376 [PMID: 16553190 DOI: 10.1080/00016340500500402]

14 **Tran KP**, Epstein JI. Mucinous adenocarcinoma of urinary bladder type arising from the prostatic urethra. Distinction from mucinous adenocarcinoma of the prostate. *Am J Surg Pathol* 1996; **20**: 1346-1350 [PMID: 8898838 DOI: 10.1097/00000478-199611000-00005]

15 **Channer JL**, Williams JL, Henry L. Villous adenoma of the bladder. *J Clin Pathol* 1993; **46**: 450-452 [PMID: 8320324 DOI: 10.1136/jcp.46.5.450]

16 **Trotter SE**, Philp B, Luck R, Ali M, Fisher C. Villous adenoma of the bladder. *Histopathology* 1994; **24**: 491-493 [PMID: 8088726 DOI: 10.1111/j.1365-2559.1994.tb00562.x]

17 **Mazzucchelli R**, Scarpelli M, Montironi R. Mucinous adenocarcinoma with superficial stromal invasion and villous adenoma of urachal remnants: a case report. *J Clin Pathol* 2003; **56**: 465-467 [PMID: 12783975 DOI: 10.1136/jcp.56.6.465]

18 **Atik E**, Akansu B, Davarci M, Inci M, Yalcinkaya F, Rifaioglu M. Villous adenoma of the urinary bladder: rare location. *Contemp Oncol* (Pozn) 2012; **16**: 276-277 [PMID: 23788894 DOI: 10.5114/wo.2012.29300]

19 **Chaudhuri A**, Sandhu DP, Xuereb J. Villous adenoma of the urinary bladder. *BJU Int* 1999; **84**: 177-178 [PMID: 10444147 DOI: 10.1046/j.1464-410x.1999.00181.x]

20 **Corica FA**, Husmann DA, Churchill BM, Young RH, Pacelli A, Lopez-Beltran A, Bostwick DG. Intestinal metaplasia is not a strong risk factor for bladder cancer: study of 53 cases with long-term follow-up. *Urology* 1997; **50**: 427-431 [PMID: 9301710 DOI: 10.1016/S0090-4295(97)00294-X]

21 **Joniau S**, Lerut E, Van Poppel H. A Giant Mucinous Adenocarcinoma Arising within a Villous Adenoma of the Urachus: Case Report and Review of the Literature. *Case Rep Med* 2009; **2009**: 818646 [PMID: 20182635 DOI: 10.1155/2009/818646]

22 **Yip SK**, Wong MP, Cheung MC, Li JH. Mucinous adenocarcinoma of renal pelvis and villous adenoma of bladder after a caecal augmentation of bladder. *Aust N Z J Surg* 1999; **69**: 247-248 [PMID: 10075375 DOI: 10.1046/j.1440-1622.1999.01540.x]

23 **O'Brien AM**, Urbanski SJ. Papillary adenocarcinoma in situ of bladder. *J Urol* 1985; **134**: 544-546 [PMID: 4032558]

24 **Ford TF**, Butcher DN, Masters JR, Parkinson MC. Immunocytochemical localisation of prostate-specific antigen: specificity and application to clinical practice. *Br J Urol* 1985; **57**: 50-55 [PMID: 2578846 DOI: 10.1111/j.1464-410X.1985.tb08984.x]

25 **Wang HL**, Lu DW, Yerian LM, Alsikafi N, Steinberg G, Hart J, Yang XJ. Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. *Am J Surg Pathol* 2001; **25**: 1380-1387 [PMID: 11684954 DOI: 10.1097/00000478-200111000-00005]

26 **Rao Q**, Williamson SR, Lopez-Beltran A, Montironi R, Huang W, Eble JN, Grignon DJ, Koch MO, Idrees MT, Emerson RE, Zhou XJ, Zhang S, Baldridge LA, Cheng L. Distinguishing primary adenocarcinoma of the urinary bladder from secondary involvement by colorectal adenocarcinoma: extended immunohistochemical profiles emphasizing novel markers. *Mod Pathol* 2013; **26**: 725-732 [PMID: 23348900 DOI: 10.1038/modpathol.2012.229]

27 **Silver SA**, Epstein JI. Adenocarcinoma of the colon simulating primary urinary bladder neoplasia. A report of nine cases. *Am J Surg Pathol* 1993; **17**: 171-178 [PMID: 8422112 DOI: 10.1097/00000478-199302000-00008]

28 **Kato Y**, Konari S, Obara W, Sugai T, Fujioka T. Concurrence of villous adenoma and non-muscle invasive bladder cancer arising in the bladder: a case report and review of the literature. *BMC Urol* 2013; **13**: 36 [PMID: 23870731 DOI: 10.1186/1471-2490-13-36]

**P-Reviewer:** Nag DSS, Vaudo G **S-Editor:** Ji FF **L-Editor:** Filipodia **E-Editor:**

**Specialty type:** Medicine, research and experimental

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

E:\1二洒文章\个案\2各部分内容\Figure1.tif

**Figure 1 Pathological analysis of the surgical specimen (hematoxylin and eosin stain, original magnification, 40 ×).** A: The tumor was composed of blunt finger-like processes lined by pseudostratified columnar cells with frequent goblet cells (arrow); B: Intracellular and extracellular abundant mucin was seen (arrow); C: The carcinomatous areas consisted of dysplastic glands and some of the glands presented with high-grade intraepithelial neoplasia (arrow).

E:\1二洒文章\个案\2各部分内容\Figure2.tif

**Figure 2 Immunohistochemical analysis of the surgical specimen (magnification, 200 ×).** A: Carcinoembryonic antigen was stained positive; B: Cytokeratin 7 was stained positive; C: Cytokeratin 20 was stained positive; D: Epithelial membrane antigen was stained positive; E: The positive ratio of Ki-67 was 60%; F: p53 was stained positive.

**Table 1 Villous adenoma of the urethra: Review of the literature**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Time of publication** | **Age in yr** | **Clinical symptoms** | **Associated adenocarcinoma** | **Treatment** | **Follow-up in mo** | **Outcome** |
| Powel *et al*[8] | 1981 | 59 | Hematuria | Yes | Transurethral resection | 15 | Alive |
| Howells *et al*[9] | 1985 | 70 | Vaginal discharge; Dysuria | No | Surgical resection | 22 | Alive |
| Raju *et al*[10] | 1987 | 58 | Asymptomatic mass increasing in size | No | Surgical resection | 72 | Alive |
| Morgan *et al*[11] | 1998 | 87 | Asymptomatic polypoid urethral mass | No | Surgical resection | 24 | Dead |
| Cheng *et al*[1] | 1999 | 81 | Hematuria | No | Unknown | Unknown | Unknown |
|  | 1999 | Unknown | Unknown | Unknown | Unknown | Unknown | Unknown |
|  | 2002 | 63 | Unknown | Unknown | Transurethral resection; Cystoprostatectomy | 84 | Alive |
| Sung *et al*[12] | 2000 | 57 | Acute attack of urinary retention | No | Transurethral resection | Unknown | Alive |
| Seibel *et al*[2] | 2002 | 93 | Unknown | Unknown | Transurethral resection; cystoprostatectomy | Unknown | Unknown |
|  | 2002 | 73 | Unknown | Unknown | Transurethral resection; prostatectomy | 24 | Local recurrence; Lung metastasis |
| Noel *et al*[13] | 2003 | 49 | Hematuria | Adenosquamous carcinoma | Surgical resection | 16 | Alive |